(R)-(+)-4-methylpyrrolidin-2-one | 260061-31-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-(+)-4-methylpyrrolidin-2-one
• 英文别名: (4R)-4-methylpyrrolidin-2-one；(R)-4-methylpyrrolidin-2-one
• CAS: 260061-31-2
• 化学式: C₅H₉NO
• mdl: MFCD00128875
• 分子量: 99.1326
• InChiKey: YRKRGYRYEQYTOH-SCSAIBSYSA-N

物化性质

• 沸点：
  240.5±9.0 °C(Predicted)
• 密度：
  0.979±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，干燥且密封。

反应信息

• 作为反应物：
  描述：

  (R)-(+)-4-methylpyrrolidin-2-one 在 4-二甲氨基吡啶 、 lithium hydroxide 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 N-BOC-4-氨基-3-甲基-丁酸
  参考文献：
  名称：

  Enantioselective Preparation of γ ‐Amino Acids and γ ‐Lactams from Nitro Olefins and Carboxylic Acids, with the Valine‐Derived 4‐Isopropyl‐5,5‐diphenyl‐1,3‐oxazolidin‐2‐one as an Auxiliary

  摘要：

  DOI：

  10.1002/(sici)1522-2675(19991215)82:12<2365::aid-hlca2365>3.0.co;2-#
• 作为产物：
  描述：

  (S)-(+)-O-(phenylseleno)acetyl-N-allylmandelamide 在 2,6-二甲基吡啶 、 偶氮二异丁腈 、 四丁基氟化铵 、 三正丁基氢锡 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 生成 (R)-(+)-4-methylpyrrolidin-2-one
  参考文献：
  名称：

  立体选择性形成光学活性的2-oxy-1,3-恶唑烷丁-4-酮和有效合成光学活性的2-吡咯烷酮

  摘要：

  在碱存在下，用TBSOTf处理（-）- O-酰基酰胺或扁桃酰胺，可以立体选择性地产生旋光的2-氧基-1,3-恶唑烷丁-4-酮，它们可用作制备旋光的仲2-羟基的有用前体。吡咯烷酮通过自由基环化和随后的一步去除扁桃酸的步骤。

  DOI：

  10.1016/s0040-4039(02)01632-5

文献信息

• [EN] ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINE ARYL-BIPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126733A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为（I）：其中A、X、Y、Z、Q、R1、R2、R3、R4、R5和n如本文所述。
• [EN] LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2<br/>[FR] DÉRIVÉS DE PYRIMIDINE À FUSION HÉTÉROARYLE LACTAME SERVANT D'INHIBITEURS D'ERBB2
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022140769A1

  公开（公告）日：2022-06-30

  The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

  本公开涉及抑制ErbB2的化合物及其组合物，包括突变形式的ErbB2，特别是那些携带Exon 20突变的形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症方面的用途，如肺癌、胶质瘤、皮肤癌、头颈癌、唾液腺癌、乳腺癌、食管癌、肝癌、胃癌、子宫癌、宫颈癌、胆道癌、胰腺癌、结肠直肠癌、肾癌、膀胱癌或前列腺癌。
• Catalytic, asymmetric azidations at carbonyls: achiral and <i>meso</i>-anhydride desymmetrisation affords enantioenriched γ-lactams
  作者：Simon N. Smith、Cristina Trujillo、Stephen J. Connon

  DOI：10.1039/d2ob01040b

  日期：——

  of azide to meso-anhydrides has been developed, promoted by novel sulfamide-substituted Cinchona alkaloid-based catalysts. Readily available glutaric anhydrides can be smoothly converted to enantioenriched hemi-acyl azides and from there to either γ-amino acids or γ-lactams.

  已经开发了一种前所未有的有机催化工艺，该工艺涉及将叠氮化物不对称加成到内消旋酸酐中，并由新型磺酰胺取代的金鸡纳生物碱基催化剂促进。容易获得的戊二酸酐可以顺利转化为富含对映体的半酰基叠氮化物，然后再转化为 γ-氨基酸或 γ-内酰胺。
• Bifunctional Iminophosphorane‐Catalyzed Enantioselective Nitroalkane Addition to Unactivated α,β‐Unsaturated Esters
  作者：Daniel Rozsar、Alistair J. M. Farley、Iain McLauchlan、Benjamin D. A. Shennan、Ken Yamazaki、Darren James Dixon

  DOI：10.1002/anie.202303391

  日期：——

  The first intermolecular enantioselective addition of nitroalkanes to unactivated α,β-unsaturated esters is described, catalyzed by a bifunctional iminophosphorane (BIMP) superbase. This fundamental synthetically relevant transformation proceeds with high enantiomeric excesses and yields over a wide range of feedstock substrates, providing pharmaceutically relevant building blocks in a single step

  描述了硝基烷烃与未活化的 α,β-不饱和酯的第一次分子间对映选择性加成，由双功能亚氨基正膦 (BIMP) 超强碱催化。这种基本的合成相关转化在多种原料底物上以高对映体过量和产率进行，只需一步即可提供药学相关的构建模块。
• The synthesis of aracemic 4-substituted pyrrolidinones and 3-substituted pyrrolidines. An asymmetric synthesis of (-)-rolipram
  作者：A. I. Meyers、Lawrence Snyder

  DOI：10.1021/jo00053a012

  日期：1993.1

  Conjugate additions of RCuCNLi to the chiral alpha,beta-unsaturated lactam 4 gives almost exclusive exo addition-a reversal in stereochemistry when cuprates were added to chiral lactam 1. The lactams 5 were transformed into 4-substituted pyrrolidinones 8 via a three-step sequence which involved decarbalkoxylation, silane reduction and metal-ammonia benzylamine cleavage. The chemical yields as well as the enantiomeric purity were very high for this process. As an example of the usefulness of this scheme, the antidepressant (-)-Rolipram was prepared in good overall yield. Furthermore, the bicyclic lactams 6 were readily transformed, using alane as the reducing agent, to 3-substituted pyrrolidines 11. Absolute configurations of 8 and 11 were confirmed by comparison with literature assignments which also gave strong support to the facial addition of the cuprates to 4.